The number of endoscopes sold is significantly higher than what the market had predicted in Ambu's second quarter. However, this has not brought about the kind of revenue that analysts had expected. The full-year outlook is maintained.
Ambu is intensifying its efforts to create the next generation of its duodenoscopes. A number of competitors are circling, and an upcoming tender is a good opportunity for income. CEO Juan Jose Gonzalez calls the new duodenoscope the biggest earner of the future.
US electronics company Bose's announced launch of a new, cheap self-tuning hearing aid won't cause sales to plummet for established hearing aid manufacturers, analysts believe. Demant welcomes the competition and WSA plans to test Bose's new solution to understanding its technology.
Sales of the drug Northera, which is no longer protected by patents, plummeted in Lundbeck's first quarter, while most other key products surpassed analysts' forecasts. This means the firm brought in more revenue than the market expected.
The tables have turned at GN Store Nord as the headset division GN Audio has now surpassed the GN Hearing business leg for several quarters. The chief of the latter, Gitte Aabo, is hardly concerned by this development as she sees it as an advantage to have a successful sister under the same parent company.
Medtech company Coloplast has set aside a further USD 33m to pay for compensation in the remaning cases over its vaginal mesh product in the US. The covid-19 crisis has delayed court cases and increased the cost of legal counsel, but the financial director expects this amount to be enough to but the cases behind them.
In an EUR 200m deal, hearing aid company Sonova has acquired audio firm Sennheiser's Consumer Division in order to better position itself in the new 'hearables market'. The Swiss company also aims to prepare for a future sales channel for low-cost hearing aids in the US, according to analyst.
After working under the radar for decades, privately-owned WS Audiology is now entering a more transparent playing field to gain better footing in the battle for the smartest brains and for partner and investor interest. Analysts view this new strategy as preparation for taking the company public.